Shinji Ohno

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

H. Sasano, N. Masuda, H. Yamashita, 2013, Breast Cancer Research and Treatment.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

K. Inoue, N. Masuda, S. Morita, 2018, Breast Cancer.

Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.

S. Kawaoka, M. Takada, H. Bando, 2024, British journal of cancer.

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

E. Tokunaga, M. Yamaguchi, N. Masuda, 2017, Breast Cancer Research and Treatment.